ABL1 and Parkinson disease: Here, we demonstrated that pharmacological inhibition of c-Abl using Ponatinib or Asciminib effectively reduces pSer129 α-Syn phosphorylation and mitigates associated transcriptional alterations, underscoring c-Abl’s central role in PD pathology.